ArticleJournal of lipid research2026
Oxylipin composition of high-density lipoprotein is altered in men and Hispanic adults with mild cognitive impairment.
Article in Journal of lipid research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Emerging Parkinson's Disease Oxylipin-Ome.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
High-density lipoprotein (HDL) oxylipins are potent inflammatory mediators. HDL dyshomeostasis and inflammation increase mild cognitive impairment (MCI) and dementia risk, which vary by gender and race/ethnicity. It is unknown whether and how HDL oxylipin profiles differ between non-MCI and MCI individuals, or if potential differences are gender- and/or race/ethnicity dependent. In this targeted lipidomics study, we profiled plasma HDL oxylipins in older (70+) adults (N = 222) with or without MCI to determine how HDL oxylipin composition relates to cognitive impairment status. HDL oxylipin concentrations were analyzed by cognitive status, gender, and race/ethnicity (non-Hispanic Black, Hispanic, and non-Hispanic white). We found a gender- and race/ethnicity-specific association between MCI and lower HDL oxylipin content, which was independent of overall HDL-c concentrations. The HDL of MCI men contained lower amounts of anti-inflammatory and vasodilatory omega (ω)3 EPA C20:5ω3-derived hydroxyeicosapentaenoic acids (HEPEs) and DHA C22:6ω3-derived hydroxydocosahexaenoic acids than that of non-MCI men. Similarly, Hispanic participants with MCI had lower HDL concentrations of EPA C20:5ω3-derived HEPEs and DHA C22:6ω3-derived hydroxydocosahexaenoic acids than non-MCI Hispanic participants. Higher HDL concentrations of EPA C20:5ω3-derived HEPEs appeared protective against MCI in both men and Hispanic individuals. Further, higher oxylipin concentrations within HDL correlated with better cognition in non-Hispanic white women. This work identifying altered HDL oxylipin composition in MCI highlights a novel dysregulated lipid signaling pathway in cognitive decline. Reduced anti-inflammatory and vasodilatory ω3 oxylipins within HDL in MCI men and Hispanic individuals provide molecular evidence linking together HDL functionality, inflammation, and dementia risk.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.